MeSH Browser

MeSH Heading: Cytarabine
Tree Number(s): D03.383.742.680.245.453; D13.570.065.300; D13.570.685.245.453
Unique ID: D003561
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D003561
Scope Note: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Entry Term(s): Ara-C; Arabinofuranosylcytosine; Arabinosylcytosine; Aracytidine; Aracytine; Cytarabine Hydrochloride; Cytonal; Cytosar; Cytosar-U; Cytosine Arabinoside; beta-Ara C
Pharm Action: Antimetabolites, Antineoplastic
Antiviral Agents
Immunosuppressive Agents
Registry Numbers: 04079A1RDZ; 33K3DB6591; 0
Related Numbers: 147-94-4; 33K3DB6591; 69-74-9
CAS Type 1 Name: 2(1H)-Pyrimidinone, 4-amino-1-beta-D-arabinofuranosyl-
NLM Classification #: QV 269
See Also: Decitabine
Public MeSH Note: 1966
History Note: 1966
Date Established: 1966/01/01
Date of Entry: 1999/01/01
Revision Date: 2018/02/28

Allowable Qualifiers: administration & dosage (AD)

adverse effects (AE)

agonists (AG)

analogs & derivatives (AA)

analysis (AN)

antagonists & inhibitors (AI)

blood (BL)

cerebrospinal fluid (CF)

chemical synthesis (CS)

chemistry (CH)

classification (CL)

economics (EC)

history (HI)

immunology (IM)

isolation & purification (IP)

metabolism (ME)

pharmacokinetics (PK)

pharmacology (PD)

poisoning (PO)

radiation effects (RE)

standards (ST)

supply & distribution (SD)

therapeutic use (TU)

toxicity (TO)

urine (UR)

Concept UI: M0005564
Registry Numbers: 04079A1RDZ
Related Numbers: 147-94-4; 33K3DB6591; 69-74-9
Scope Note: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Terms: Cytarabine Preferred Term
Term UI T010339
Date01/01/1999
LexicalTag NON
ThesaurusID; Arabinofuranosylcytosine
Term UI T010334
Date03/05/1976
LexicalTag NON
ThesaurusID UNK (19XX); Arabinosylcytosine
Term UI T010335
Date03/29/1974
LexicalTag NON
ThesaurusID UNK (19XX); Aracytidine
Term UI T010336
Date11/20/1980
LexicalTag NON
ThesaurusID UNK (19XX); Cytosine Arabinoside
Term UI T010340
Date03/29/1974
LexicalTag NON
ThesaurusID UNK (19XX)

Cytarabine MeSH Descriptor Data 2024